杜皮鲁玛
医学
美波利祖马布
奥马佐单抗
鼻息肉
鼻塞
皮肤病科
临床试验
食品药品监督管理局
耐火材料(行星科学)
鼻窦炎
重症监护医学
特应性皮炎
内科学
免疫学
鼻子
外科
药理学
哮喘
免疫球蛋白E
嗜酸性粒细胞
抗体
物理
天体生物学
作者
Matthew J. Lelegren,Sam Y. Son,Joseph K. Han,Kent K. Lam
出处
期刊:Immunotherapy
[Future Medicine]
日期:2022-05-04
卷期号:14 (8): 655-662
被引量:15
标识
DOI:10.2217/imt-2021-0310
摘要
Chronic rhinosinusitis with nasal polyposis is a heterogenous disease with complex underlying pathophysiologic mechanisms. Biologics have been proven to be an effective add-on therapeutic option in severe and/or refractory cases. Currently, dupilumab, omalizumab and mepolizumab have phase III data to support their use in these patients and have received approval from the United States Food and Drug Administration specifically for the treatment of nasal polyposis. Each of these biologics has shown its ability to reduce nasal polyp size and improve nasal congestion/obstruction and sense of smell, but additional research is needed to directly compare the efficacy and safety of the different biologic agents for different nasal polyposis endotypes.
科研通智能强力驱动
Strongly Powered by AbleSci AI